Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) ...

WATERTOWN, Mass. , March 04, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with multispecific antibodies that address the ...

Hereditary hemorrhagic telangiectasia (HHT) is a rare genetic disorder of the blood vessels. It is also known as Osler-Weber-Rendu. It is characterized by blood vessles that are missing normal ...

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...

Cure HHT has led the development of the first international consensus on how to define, measure, and track bleeding in Hereditary Hemorrhagic Telangiectasia (HHT), published July 15 in the American ...

Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of multiple arteriovenous malformations (AVMs) that lack intervening capillaries and result in direct connections between ...

People with HHT have a near-typical life expectancy as long as they follow their treatment plan and undergo regular screening for complications. Hereditary hemorrhagic telangiectasia (HHT) is a rare ...

Atavistik Bio’s $120 million Series B financing bolsters its push to advance first-in-class, allosteric small-molecule therapies for HHT and MPNs, leveraging its AMPS platform to selectively target ...

To assess the utility of US health insurance data for surveillance of hereditary hemorrhagic telangiectasia, an autosomal-dominant blood vasculature disorder with an estimated prevalence of 1.5–2.0 ...

Medical imaging, like MRI, CT, and ultrasound, plays a vital role in diagnosing HHT, formerly known as Osler-Weber-Rendu syndrome. Imaging can help guide treatment and improve your outlook with HHT.

Hereditary hemorrhagic telangiectasia (HHT) can be fatal. However, it does not affect the average life expectancy of most people. Complications can occur when blood vessels rupture in vital organs.